Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 4, 2005, Pages 698-703

  Kränkel, Nicolle ^a   Adams, Volker ^a   Linke, Axel ^a   Gielen, Stephan ^a   Erbs, Sandra ^a   Lenk, Karsten ^a   Schuler, Gerhard ^a   Hambrecht, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Circulating progenitor cells; Endothelium; Hyperglycemia; Nitric oxide; Vascular biology

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; GELATINASE B; GLUCOSE; NITRIC OXIDE;

ADULT; ARTICLE; CELL CYCLE; CELL FUNCTION; CELL SURVIVAL; CIRCULATION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; OSMOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REDUCTION; STEM CELL;

ADOLESCENT; ADULT; APOPTOSIS; CELL CYCLE PROTEINS; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIABETES COMPLICATIONS; FEMALE; GLUCOSE; HEMATOPOIETIC STEM CELLS; HUMANS; HYPERGLYCEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER;

EID: 16244399236     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000156401.04325.8f     Document Type: Article

References (40)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14:S1-S85.
2. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002;5:561-568.
3. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44:129-146.
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of lonf-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
5. Hibbert B, Olsen S, O'Brien E. Involvement of progenitor cells in vascular repair. Trends Cardiovasc Med. 2003;13:322-326.
6. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103:1231-1236.
7. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angioneogenesis. Science. 1997;275:964-967.
8. Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher A, Dimmeler S. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 2002;16:706-708.
9. Dimmeler S, Dernbach E, Zeiher A. Phosphorylation of the Endothelial Nitric Oxide Synthase as Ser-1177 is Required for VEGF-induced Endothelial Cell Migration. FEBS Lett. 2000;477:258-262.
10. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher A. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
11. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher A, Dimmeler S. Essential Role of Endothelial Nitric Oxide Synthase for Mobilization of Stem and Progenitor Cells. Nat Med. 2003;9:1370-1376.
12. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jürgens K, Miche E, Böhm M, Nickenig G. Physical training increases endothelial progenitor cells, inhibition of neointima formation, and enhances angiogenesis. Circulation. 2004;109:220-226.
13. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem. 2001;276:17625-17628.
14. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:e1-e7.
15. Tepper O, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures. Circulation. 2002;106:2781-2786.
16. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Rabelink TJ, van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type I diabetes. Diabetes. 2004;53:195-199.
17. Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Increase of Circulating Endothelial Progenitor Cells in Patients With Coronary Artery Disease After Exercise-Induced Ischemia. Arlerioscler Thromb Vasc Biol. 2004;24:684-690.
18. Hambrecht R, Adams V, Erbs S, Linke A, Kränkel N, Shu Y, Baither Y, Gielen S, Gummert JF, Mohr FW, Schuler G. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003;107:3152-3158.
19. Ascenzi P, Desideri A, Amiconi G, Bertollini A, Bolognesi M, Castagnola M, Coletta M, Brunori M. Effect of inositol hexakisphosphate on the spectroscopic properties of the nitric oxide derivative of ferrous naturally glycated human hemoglobin HbAIc. J Inorg Biochem. 1988;34:19-24.
20. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188-193.
21. Makimattila S, Virkamaki A, Groop PH, Cockroft JR, Utriainen T, Fagerudd J, Yki-Jarvinen H. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation. 1996;94:1276-1282.
22. Gaenzer H, Neumayr G, Marschang P, Sturm W, Lechleitner M, Foger B, Kirchmair R, Patsch J. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol. 2002;89:431-434.
23. Chen JS, Lee HS, Jin JS, Chen A, Lin SH, Ka SM, Lin YF. Attenuation of mouse mesangial cell contractility by high glucose and mannitol: involvement of protein kinase C and focal adhesion kinase. J Biomed Sci. 2004;11:142-151.
24. Kabat A, Dhein S: L-arginine supplementation reprevents from the development of endothelial dysfunction in hyperglycemia. Thorac Cardiovasc Surg. In press.
25. Lorenzi M, Nordberg JA, Toledo S. High Glucose prolongs cell-cycle traversal of cultured human endothelial cells. Diabetes. 1987;36:1261-1267.
26. Brizzi MF, Dentelli P, Pavan M, Rosso A, Gambino R, Grazia de Cesaris M, Garbarino G, Camussi G, Pagano G, Pegoraro L. Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf). J Clin Invest. 2002;109:111-119.
27. Kimura I, Honda R, Okai H, Okabe M. Vascular endothelial growth factor promotes cell-cycle transition from G0 to G1 phase in subcultured endothelial cells of diabetic rat thoracic aorta. Jpn J Pharmacol. 2000;83:47-55.
28. Minami R, Muta K, Umemura T, Motomura S, Abe Y, Nishimura J, Nawata H. p16(INK4a) induces differentiation and apoptosis in erythroid lineage cells. Exp Hematol. 2003;31:355-362.
29. Shukla S, Gupta S. Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog. 2004;39:114-126.
30. Kim SK, Wang KC, Cho BK, Lim SY, Kim YY, Oh CW, Chun YN, Lee CT, Kim HJ. Adenoviral p16/CDKN2 gene transfer to malignant glioma: role of p16 in growth, invasion, and senescence. Oncol Rep. 2003;10:1121-1126.
31. Lopez-Farre A, Sanchez de Miguel L, Caramelo C, Gomez-Macias J, Garcia R, Mosquera JR, de Frutos T, Millas I, Rivas F, Echezarreta G, Casado S. Role of nitric oxide in autocrine control of growth and apoptosis of endothelial cells. Am J Physiol. 1997;272:H760-H768.
32. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001;108:1341-1348.
33. 1179. J Biol Chem. 2001;276:30392-30398.
34. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow nighe requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
35. Rafii S, Avecilla S, Shmelkov S, Shido K, Tejada R, Moore MA, Heissig B, Hattori K. Angiogenic Factors Reconstitute Hematopoiesis by Recruiting Stem Cells From Bone Marrow Micrienvironment. Ann N Y Acad Sci. 2003;996:49-60.
36. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A Novel Antisense Inhibitor of MMP-9 Attenuates Angiogenesis, Human Prostate Cancer Cell Invasion and Tumorigenicity. Cancer Gene Ther. 2003;10:823-832.
37. El-Akool S, Kleinert H, Hamada FM, Abdelwahab MH, Forstermann U, Pfeilschifter J, Eberhardt W. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol. 2003;23:4901-4916.
38. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 2002;95:1902-1910.
39. Johanning JM, Armstrong PJ, Franklin DP, Han DC, Carey DJ, Elmore JR. Nitric oxide in experimental aneurysm formation: early events and consequences of nitric oxide inhibition. Ann Vasc Surg. 2002;16:65-72.
40. Marcet-Palacios M, Graham K, Cass C, Befus AD, Mayers I, Radomski MW. Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinsa-9 in vascular smooth muscle. J Pharmacol Exp Ther. 2003;307:429-436.